New Data Confirm Safety Of GT Medical’s GammaTile Therapy For Brain Tumors
GT Medical is touting results from a validation study showing its GammaTile therapy controls the regrowth of brain tumors with a low rate of adverse events.
You may also be interested in...
Start-Up Spotlight: GT Medical Technologies' GammaTile Brings Brachytherapy Directly To Brain Tumors
Arizona-based GT Medical Technologies is ramping up commercialization of its GammaTile surgically targeted radiation therapy for patients with recurrent intracranial neoplasms. GammaTile already received 510(k) clearance, but continues to develop clinical evidence showing that GammaTile improves control of brain cancer following excision surgery and prolongs patient-survival.
As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.
The Texas company is planning to sell 30,000 at-home sample collection kits for COVID-19 testing beginning on 23 March.